Barclays
FBRX icon

Barclays’s Forte Biosciences FBRX Stock Holding History

Barclays’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$344K Sell
13,268
-10,843
-45% -$312K ﹤0.01% 3397
2025
Q4 		$658K Buy
24,111
+23,291
+2,840% +$408K ﹤0.01% 3697
2025
Q3 		$12.3K Buy
+820
New +$9.45K ﹤0.01% 5005
2024
Q4 		– Sell
-1
Closed -$6 – 5337
2024
Q3 		$6 Buy
+1
New +$10 ﹤0.01% 5247
2022
Q3 		– Sell
-26
Closed -$1K – 4898
2022
Q2 		$1K Sell
26
-73
-74% -$2.32K ﹤0.01% 4934
2022
Q1 		$3K Buy
+99
New +$3.75K ﹤0.01% 4751
2020
Q2 		– Sell
-19
Closed -$9K – 5757
2020
Q1 		$9K Sell
19
-38
-67% -$14.8K ﹤0.01% 5840
2019
Q4 		$11K Buy
57
+27
+90% +$6.12K ﹤0.01% 6081
2019
Q3 		$7K Sell
30
-6
-17% -$9.11K ﹤0.01% 6414
2019
Q2 		$91K Buy
36
+17
+89% +$50.4K ﹤0.01% 5758
2019
Q1 		$75K Buy
+19
New +$73.4K ﹤0.01% 5580
2018
Q4 		– Sell
-18
Closed -$77.5K – 6793
2018
Q3 		$105K Buy
18
+14
+350% +$53.3K ﹤0.01% 5497
2018
Q2 		$13K Sell
4
-11
-73% -$40.3K ﹤0.01% 6403
2018
Q1 		$68K Buy
15
+7
+88% +$32.4K ﹤0.01% 5651
2017
Q4 		$29K Sell
8
-14
-64% -$55.9K ﹤0.01% 6091
2017
Q3 		$105K Buy
+22
New +$98K ﹤0.01% 4897
2017
Q2 		– Hold
0
– – – 6725

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

Barclays's FBRX Position: Q1 2026 in Review

Barclays reduced its Forte Biosciences (FBRX) stake by 45% in Q1 2026, selling an estimated $312K and leaving 13,268 shares worth $344K. The position accounts for ﹤0.01% of the portfolio, ranked #3397.

Barclays first reported a position in FBRX in Q3 2017 and has held it in 16 quarters since. The position peaked at $658K in Q4 2025. 68 funds tracked by Wall St. Rank hold FBRX as of Q1 2026.

  • Barclays held 13,268 shares of Forte Biosciences worth $344K as of Q1 2026.
  • Barclays sold 10,843 Forte Biosciences shares in Q1 2026, an estimated $312K.
  • Forte Biosciences made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3397 holding.
  • Barclays first reported a position in Forte Biosciences in Q3 2017 and has held it in 16 quarters since.
  • Barclays's Forte Biosciences position peaked at $658K in Q4 2025.
  • 68 funds tracked by Wall St. Rank held Forte Biosciences as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.